ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MPH Mereo Biopharma Group Plc

26.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Mereo Biopharma Group Plc LSE:MPH London Ordinary Share GB00BZ4G2K23 ORD GBP0.003 (REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.50 26.00 27.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Mereo BioPharma Group plc Notice of AGM (2404C)

24/06/2016 12:47pm

UK Regulatory


Mereo Biopharma (LSE:MPH)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Mereo Biopharma Charts.

TIDMMPH

RNS Number : 2404C

Mereo BioPharma Group plc

24 June 2016

24 June 2016

NOTICE OF ANNUAL GENERAL MEETING

Mereo BioPharma Group plc ("Mereo" or the "Company") (AIM:MPH), a UK-based specialty biopharmaceutical company, gives notice of the following:

-- the Notice of Annual General Meeting ("AGM") and Form of Proxy have been sent to shareholders. The Notice of AGM is also available in the Financial Calendar page of the Company's website; and

-- that its AGM will be held on Monday 18 July 2016 at the offices of Proskauer Rose (UK) LLP, 110 Bishopsgate, London EC2N 4AY at 10.00 a.m.

Enquiries:

 
 
                                            +44 (0)333 
   Mereo BioPharma Group plc                023 7319 
 Denise Scots-Knight, Chief Executive 
  Officer 
 Richard Bungay, Chief Financial 
  Officer & COO 
 
 
   Cantor Fitzgerald Europe (Nominated      +44 (0)20 
   Adviser and Broker)                      7894 7000 
 Phil Davies 
 Will Goode 
 Rick Thompson 
 Callum Butterfield 
 
 
                                            +44 (0)20 
   RBC Capital Markets (Joint Broker)       7653 4000 
 Paul Tomasic 
 Rupert Walford 
 Thomas Stockman 
 Laura White 
 
 
   FTI Consulting (Public Relations         +44 (0)20 
   Adviser)                                 3727 1000 
 Ben Atwell 
 Simon Conway 
 Brett Pollard 
 

About Mereo

Mereo is a UK-based specialty biopharmaceutical company focused on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life.

Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines.

Mereo's initial mid-late stage portfolio consists of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need, which it acquired from Novartis Pharmaceuticals in July 2015. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Since that time the Company has initiated a Phase 2 study and a Phase 2b study in relation to two of the product candidates in 2016 and intends to commence registration studies during H2 2016 for the third product candidate. Additional product opportunities are under evaluation.

Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON.

Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOAAKQDQDBKDPAB

(END) Dow Jones Newswires

June 24, 2016 07:47 ET (11:47 GMT)

1 Year Mereo Biopharma Chart

1 Year Mereo Biopharma Chart

1 Month Mereo Biopharma Chart

1 Month Mereo Biopharma Chart

Your Recent History

Delayed Upgrade Clock